Anti-trypanosomatid drug discovery: progress and challenges.

Nat Rev Microbiol

Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, UK.

Published: January 2023

Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis cause substantial death and morbidity, particularly in low- and middle-income countries. Although the situation has improved for human African trypanosomiasis, there remains an urgent need for new medicines to treat leishmaniasis and Chagas disease; the clinical development pipeline is particularly sparse for Chagas disease. In this Review, we describe recent advances in our understanding of the biology of the causative pathogens, particularly from the drug discovery perspective, and we explore the progress that has been made in the development of new drug candidates and the identification of promising molecular targets. We also explore the challenges in developing new clinical candidates and discuss potential solutions to overcome such hurdles.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395782PMC
http://dx.doi.org/10.1038/s41579-022-00777-yDOI Listing

Publication Analysis

Top Keywords

chagas disease
12
drug discovery
8
human african
8
african trypanosomiasis
8
anti-trypanosomatid drug
4
discovery progress
4
progress challenges
4
challenges leishmaniasis
4
leishmaniasis visceral
4
visceral cutaneous
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!